Course: Cancer Immunotherapy Today and Tomorrow- 10/27/2018
Immune-based cancer therapies are producing durable responses and significant overall survival times for more tumor
types. In the past year, the FDA significantly expanded the immunotherapy armamentarium when it approved CAR T-cells
for treating adults with certain B-cell lymphomas. This CME event will deliver scientific discussion and clinical strategies of
interest to researchers, oncologists, primary care physicians and specialists.
The course will provide concise summaries of today’s immunotherapies and those that are on the way. Registrants will
receive the curriculum on a flash drive on the day of the event.
- Therapeutic role and management of CAR T-cell therapy
- Breakthroughs on the horizon: What will be next?
- Review of immunotherapy science
- Personalized cancer vaccines for hematologic malignancies
- Checkpoint blockade therapies for solid tumors: melanoma and breast, kidney, lung and pancreatic tumors
- Impact of combination therapies
- Managing toxicity and other immune-related adverse events
- Current clinical trials.
Keynote Speakers (partial list):
John F. DiPersio, MD, PhD,Washington University School of Medicine in St. Louis
Mario Sznol, MD,Yale Cancer Center
David Avigan, MD, and David McDermott, MD, directors, and Jacalyn Rosenblatt, MD, deputy director
Immunotherapy Institute, Cancer Center at Beth Israel Deaconess Medical Center